Bone Marrow Transplant Market Synopsis

Bone Marrow Transplant Market Size Was Valued at USD 11.02 Billion in 2023 and is Projected to Reach USD 15.55 Billion by 2032, Growing at a CAGR of 3.90% From 2024-2032.

Bone Marrow Transplant (BMT) Market relates to procedures that transplant stem cells/bone marrow originating either from a donor or alternatively, the patient to cure blood disorders/ diseases which include leukemia, lymphoma and multiple myeloma among others. This process can prove helpful in reversing the many hematological diseases that may result from the body’s inability to make healthy blood cell.

• The Bone Marrow Transplant market has also shown a constant rise over the recent period as a result of growing cases of hematological malignancies, genetic disorders and autoimmune diseases. The incidence of cancers; particularly haematological malignancies including leukemia and lymphoma embraced throughout the world has influenced the use of efficacious treatment approaches for example BMT. In addition, technological innovations in medical care, enhanced knowledge about the technique of transplantation techniques, and advance short-term care are helping patient achieve better outcomes and higher recovery ratios. Market growth has also been attributed by the increased perception by patient’s and healthcare practitioners regarding the utility of BMT.
• Regionally, the market divides into North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. North America has large market share because of proper healthcare facilities, more transplantations of BM, and adequate focus on R&D in the field. This region is also expected to gain importance in the future because the frequency of BMT procedures is also enhancing, healthcare standards are evolving and there is greater investment in healthcare facilities throughout the Asia Pacific area. In conclusion, increased incidence of diseases relatable to bone marrow transplants, improvement in the methods and supports care have created a positive influence on the sector.

Bone Marrow Transplant Market Trend Analysis

Increased Adoption of Stem Cell Therapies

• The increase in the awareness of the stem cell treatments is the emerging factor that affect the Bone Marrow Transplant market. Novel stem cell therapies have emerged as an option different from conventional BMT offering new options for patients with haematological diseases. Planned with this approach there is a possibility of using less invasive treatments and it also has the advantage of shorter duration of rehabilitation compared to treatment that involves bone marrow transplants. Further, clinical neuroscience has also been emerging as a novel area in regenerative medicine and biotechnology that is consistently driving new studies and improved treatment therapies that are now frequently utilised in practice settings.
• This trend is evidenced by increased attention to and expansion of clinical trials and research projects in the field of stem cell treatment of various blood diseases. This is because the efficacy together with the efficiency of the therapy has been enhanced by the increased knowledge of healthcare givers regarding the treatments and demand for stem cell treatments is also expected to increase significantly. This change to less invasive, or minimally invasive approaches, may potentially improve patient satisfaction and care, thus promoting positive growth within the overall market looking at bone marrow transplants.

Growing Demand for Cord Blood Transplantation

• An emergence that has been identified within the Bone Marrow Transplant market is the increasing use of cord blood transplantation. A relatively new source of HSC for BMT is umbilical cord blood that is collected at the time of birth. The growing understanding of the importance of cord blood banking coupled with the numerous uses of stem cells in managing different blood related diseases is a tremendous market driver. Consumers are gaining more and more knowledge about the possibilities of using cord blood in future as the source for transplants, which helps to explain the increase in demand.
• Further, innovations are being made in relation to preserving and processing cords blood, which are making cord blood stem cells more available for use. The specific segment will thus see growth from the setting up of specialized cord blood banks, and better methods in retrieving and storing the same. While using cord blood is accepted as a superior source of stem cells compared to conventional bone marrow sources, as the market for cord blood transplantation expands significantly the overall Bone Marrow Transplant market stands to benefit.

Bone Marrow Transplant Market Segment Analysis:

Bone Marrow Transplant Market Segmented based on Transplant Type, Disease Indication, and End User.

By  Transplant Type, Autologous segment is expected to dominate the market during the forecast period

• Based on the transplantation type, global Bone Marrow Transplant market segments could be studied into two types: autologous transplantation and allogeneic transplantation. Self-transplantation means the stem cells needed are harvested from the patient, processed then returned back to the same patient after they have been administered high doses of chemicals aimed at destroying the affected cells. On this method, there is little chance of rejection and other related complications arising from matching the donors. The most common among them is autologous transplant which is preferred for diseases that are hard to treat such as multiple myeloma and specific kinds of lymphoma.
• Allogeneic transplants, in contrast, require using the stem cells from a donor that maybe related or an unrelated donor. This type of transplantation is required where the patient can no longer have use of his/her own stem cells because of a disease or previous treatments. No questions, allogeneic transplants have a higher rate of untoward effects, for example, graft-ver-sus-host disease; however, potentially easier to sense cure for the more severe diseases. The kind of transplantation that is carried out whether autologous or allogeneic depends on the condition of the recipient, type of disease and matching in the donor.

By End User , Hospitals segment held the largest share in 2023

• The Bone Marrow Transplant market by end users is categorized into hospitals, multispecialty clinics, ambulatory surgical centers and others. Clinics still appear as the most dominant kind of facilities, because BMT is normally performed by specialized teams within hospital settings. The existence of facilities for hematology-oncology departments, transplant coordinators and a complete patient care in the hospitals enhance the administration of the bone marrow transplant cases hence improved patient results.
• Other models that are also gaining significance in the BMT include multispecialty clinics and ambulatory surgical centres. These facilities avail a more patients’ friendly environment compared to conventional hospitals or clinics. Some of the key drivers discussed in this research include increased number of outpatient services, technological innovations that enable some transplant procedures to be conducted in such centres hence increasing the size of the market. Related to the trends in the evolution of the healthcare delivery model, a role of the identified end users in the bone marrow transplant environment will grow, which will affect the evolution of the market.

Bone Marrow Transplant Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• As of today, North America remains as the market leader of the Bone Marrow Transplant. Availability of effective healthcare facilities with increased numbers of speciality care centres and strong established networks of transplant centres are few factors that have made this region the leader in this market. In particular, the United States has significant experience in the field of BMT and, today is the base for several leading centers of transplantations and researches. Another advantage is marked investment in health research in the area, improving transplant surgery, and more efficient handling of the patients on organ transplant prosthetic devices.
• Furthermore, the high incidence of hematological malignancies and rising knowledge of BMT as a therapeutic choice fuel market expansion in North America. Other memoranda of understanding and government and non-profit organ available research and education for the field of bone marrow transplantation strengthen the region as the leader. Likely, North America which is actively progressing in patient care outcomes and accessibility is expected to remain the leading in the Bone Marrow Transplant market.

Active Key Players in the Bone Marrow Transplant Market

• Novartis (Switzerland)
• Bristol-Myers Squibb (USA)
• Amgen (USA)
• Gilead Sciences (USA)
• Roche (Switzerland)
• Celgene (USA)
• Merck (Germany)
• Takeda Pharmaceutical Company (Japan)
• Eli Lilly and Company (USA)
• Pfizer (USA)
• AstraZeneca (UK)
• Mylan N.V. (USA)
• Jazz Pharmaceuticals (Ireland)
• Grifols (Spain)
• Karyopharm Therapeutics (USA) and Others Active Player

Key Industry Developments in the Bone Marrow Transplant Market

• September 2023: BioLineRx Ltd. announced FDA approval for APHEXDA™ (motixafortide) with filgrastim for mobilizing hematopoietic stem cells in multiple myeloma patients for autologous transplantation. APHEXDA is administered through subcutaneous injection.
• August 2023: Massachusetts General Hospital (MGH) officially inaugurated the Legorreta Center for Clinical Transplant Tolerance, the world's first center to prevent organ rejection post-transplant without requiring lifelong immunosuppressive medications.
• September 2021: Sanofi merged with Kadmon Holdings, Inc., adding Rezurock™ (belumosudil) to its transplant portfolio. Rezurock, an FDA-approved treatment for chronic graft-versus-host disease, caters to patients aged 12 and above who have not responded to at least two prior systemic therapies.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Bone Marrow Transplant Market by Transplant Type
 4.1 Bone Marrow Transplant Market Snapshot and Growth Engine
 4.2 Bone Marrow Transplant Market Overview
 4.3 Autologous
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Autologous: Geographic Segmentation Analysis
 4.4 Allogeneic
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Allogeneic: Geographic Segmentation Analysis

Chapter 5: Bone Marrow Transplant Market by Disease Indication
 5.1 Bone Marrow Transplant Market Snapshot and Growth Engine
 5.2 Bone Marrow Transplant Market Overview
 5.3 Leukemia
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Leukemia: Geographic Segmentation Analysis
 5.4 Lymphoma
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Lymphoma: Geographic Segmentation Analysis
 5.5 Myeloma
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Myeloma: Geographic Segmentation Analysis
 5.6 Others
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Others: Geographic Segmentation Analysis

Chapter 6: Bone Marrow Transplant Market by End User
 6.1 Bone Marrow Transplant Market Snapshot and Growth Engine
 6.2 Bone Marrow Transplant Market Overview
 6.3 Hospitals
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospitals: Geographic Segmentation Analysis
 6.4 Multispecialty Clinics
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Multispecialty Clinics: Geographic Segmentation Analysis
 6.5 Ambulatory Surgical Centers
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Ambulatory Surgical Centers: Geographic Segmentation Analysis
 6.6 Others
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Others: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Bone Marrow Transplant Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 NOVARTIS (SWITZERLAND)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 BRISTOL-MYERS SQUIBB (USA)
 7.4 AMGEN (USA)
 7.5 GILEAD SCIENCES (USA)
 7.6 ROCHE (SWITZERLAND)
 7.7 CELGENE (USA)
 7.8 MERCK (GERMANY)
 7.9 TAKEDA PHARMACEUTICAL COMPANY (JAPAN)
 7.10 ELI LILLY AND COMPANY (USA)
 7.11 PFIZER (USA)
 7.12 ASTRAZENECA (UK)
 7.13 MYLAN N.V. (USA)
 7.14 JAZZ PHARMACEUTICALS (IRELAND)
 7.15 GRIFOLS (SPAIN)
 7.16 KARYOPHARM THERAPEUTICS (USA)
 7.17 OTHERS ACTIVE PLAYERS.

Chapter 8: Global Bone Marrow Transplant Market By Region
 8.1 Overview
 8.2. North America Bone Marrow Transplant Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Transplant Type
  8.2.4.1 Autologous
  8.2.4.2 Allogeneic
  8.2.5 Historic and Forecasted Market Size By Disease Indication
  8.2.5.1 Leukemia
  8.2.5.2 Lymphoma
  8.2.5.3 Myeloma
  8.2.5.4 Others
  8.2.6 Historic and Forecasted Market Size By End User
  8.2.6.1 Hospitals
  8.2.6.2 Multispecialty Clinics
  8.2.6.3 Ambulatory Surgical Centers
  8.2.6.4 Others
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Bone Marrow Transplant Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Transplant Type
  8.3.4.1 Autologous
  8.3.4.2 Allogeneic
  8.3.5 Historic and Forecasted Market Size By Disease Indication
  8.3.5.1 Leukemia
  8.3.5.2 Lymphoma
  8.3.5.3 Myeloma
  8.3.5.4 Others
  8.3.6 Historic and Forecasted Market Size By End User
  8.3.6.1 Hospitals
  8.3.6.2 Multispecialty Clinics
  8.3.6.3 Ambulatory Surgical Centers
  8.3.6.4 Others
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Bone Marrow Transplant Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Transplant Type
  8.4.4.1 Autologous
  8.4.4.2 Allogeneic
  8.4.5 Historic and Forecasted Market Size By Disease Indication
  8.4.5.1 Leukemia
  8.4.5.2 Lymphoma
  8.4.5.3 Myeloma
  8.4.5.4 Others
  8.4.6 Historic and Forecasted Market Size By End User
  8.4.6.1 Hospitals
  8.4.6.2 Multispecialty Clinics
  8.4.6.3 Ambulatory Surgical Centers
  8.4.6.4 Others
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Bone Marrow Transplant Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Transplant Type
  8.5.4.1 Autologous
  8.5.4.2 Allogeneic
  8.5.5 Historic and Forecasted Market Size By Disease Indication
  8.5.5.1 Leukemia
  8.5.5.2 Lymphoma
  8.5.5.3 Myeloma
  8.5.5.4 Others
  8.5.6 Historic and Forecasted Market Size By End User
  8.5.6.1 Hospitals
  8.5.6.2 Multispecialty Clinics
  8.5.6.3 Ambulatory Surgical Centers
  8.5.6.4 Others
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Bone Marrow Transplant Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Transplant Type
  8.6.4.1 Autologous
  8.6.4.2 Allogeneic
  8.6.5 Historic and Forecasted Market Size By Disease Indication
  8.6.5.1 Leukemia
  8.6.5.2 Lymphoma
  8.6.5.3 Myeloma
  8.6.5.4 Others
  8.6.6 Historic and Forecasted Market Size By End User
  8.6.6.1 Hospitals
  8.6.6.2 Multispecialty Clinics
  8.6.6.3 Ambulatory Surgical Centers
  8.6.6.4 Others
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Bone Marrow Transplant Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Transplant Type
  8.7.4.1 Autologous
  8.7.4.2 Allogeneic
  8.7.5 Historic and Forecasted Market Size By Disease Indication
  8.7.5.1 Leukemia
  8.7.5.2 Lymphoma
  8.7.5.3 Myeloma
  8.7.5.4 Others
  8.7.6 Historic and Forecasted Market Size By End User
  8.7.6.1 Hospitals
  8.7.6.2 Multispecialty Clinics
  8.7.6.3 Ambulatory Surgical Centers
  8.7.6.4 Others
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research